Pfizer's Xtandi Gets FDA Nod for Expanded Patient Population

Pfizer Inc. PFE and its Japanese partner Astellas announced that the FDA has granted approval to a supplemental new drug application (sNDA) for prostate cancer drug, Xtandi. With the latest approval, the label of Xtandi has been expanded to include an early-stage patient population - non-metastatic castration-resistant prostate cancer (“CRPC”).